Newborn screening for cystic fibrosis in Switzerland - Consequences after analysis of a 4 months pilot study

Journal of Cystic Fibrosis

Volumn 12, Issue 6, 2013, Pages 667-674

  Torresani, Toni ^a   Fingerhut, Ralph ^a   Rueegg, Corina S ^b   Gallati, Sabina ^c   Kuehni, Claudia E ^b   Baumgartner, Matthias R ^a   Barben, Juerg ^d   Barazzone, Constance ^e   Casaulta, Carmen ^e   Mornand, Anne ^e   Eng, Peter ^e   Hafen, Gaudenz ^e   Hammer, Jürg ^e   Möller, Alexander ^e   Müller, Dominik ^e   Regamey, Nicolas ^e   Rochat, Isabelle ^e   Schiller, Barbara ^e   Schöni, Martin H ^e   Spinas, Renate ^e   Spalinger, Johannes ^e   Trachsel, Daniel ^e   Zanolari, Maura ^e   more..

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^d Ostschweizer Children's Hospital   (Switzerland)

^e NONE

Author keywords

Cystic fibrosis; Immunoreactive trypsinogen; Newborn screening; Recall rate

Indexed keywords

TRYPSINOGEN;

ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CYSTIC FIBROSIS; DIAGNOSTIC TEST ACCURACY STUDY; GENE MUTATION; GENOTYPE; HUMAN; IMMUNOLOGY TEST KIT; INFANT; MAJOR CLINICAL STUDY; NEWBORN SCREENING; PILOT STUDY; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; SWEAT TEST; SWITZERLAND;

CYSTIC FIBROSIS; IMMUNOREACTIVE TRYPSINOGEN; NEWBORN SCREENING; RECALL RATE;

ALGORITHMS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DNA MUTATIONAL ANALYSIS; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING; PILOT PROJECTS; SENSITIVITY AND SPECIFICITY; SWEAT; SWITZERLAND; TRYPSINOGEN;

EID: 84888021984     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2013.04.008     Document Type: Article

References (21)

1. Barben J., Gallati S., Fingerhut R., Schoeni M.H., Baumgartner M.R., Torresani T. Retrospective analysis of stored dried blood spots from children with cystic fibrosis and matched controls to assess the performance of a proposed newborn screening protocol in Switzerland. J Cyst Fibros 2012, 11:332-336.
2. Barben J., Torresani T., Schoeni M., Gallati S., Baumgartner M.R. Neugeborenen-Screening auf Cystische Fibrose - ab 1. Januar 2011 auch in der Schweiz. Schweiz Arzteztg 2011, 92:18-20.
3. Wilcken B., Wiley V., Sherry G., Bayliss U. Neonatal screening for cystic fibrosis: a comparison of two strategies for case detection in 1.2million babies. J Pediatr 1995, 127:965-970.
4. Southern K.W., Munck A., Pollitt R., Travert G., Zanolla L., Dankert-Roelse J., et al. A survey of newborn screening for cystic fibrosis in Europe. J Cyst Fibros 2007, 6:57-65.
5. Castellani C., Southern K.W., Brownlee K., Dankert Roelse J., Duff A., Farrell M., et al. European best practice guidelines for cystic fibrosis neonatal screening. J Cyst Fibros 2010, 8:153-173.
6. Comeau A.M., White T.B., Campbell P.W., Hoffman G., Parad R.B., Wilfond B.S., et al. Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report. Pediatrics 2007, 119:e495-e518.
7. Blomberg K.R., Mukkala V.-M., Hakala H.H.O., Mäkinen P.H., Suonpää M.U., Hemmilä I.A. A dissociative fluorescence enhancement technique for one-step time-resolved immunoassays. Anal Bioanal Chem 2011, 399:1677-1682.
8. Ranieri E., Lewis B.D., Gerace R.L., Ryall R.G., Morris C.P., Nelson P.V., et al. Neonatal screening for cystic fibrosis using immunoreactive trypsinogen and direct analysis: four years' experience. BMJ 1994, 308:1469-1472.
9. Wilcken B. Newborn screening for cystic fibrosis: techniques and strategies. J Inherit Metab Dis 2007, 30:537-543.
10. Heinonen P., Iitiä A., Torresani T., Lövgren T. Simple triple-label detection of seven cystic fibrosis mutations by time resolved fluorometry. Clin Chem 1997, 43:1142-1150.
11. CLSI Sweat testing: sample collection and quantitative chloride analysis; approved guideline 2009, Clinical and Laboratory Standards Institute, Wayne, PA, USA. 3rd ed.
12. Farrell P.M., Rosenstein B.J., White T.B., Accurso F.J., Castellani C., Cutting G.R., et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation Consensus Report. J Pediatr 2008, 153:S4-S14.
13. Mayell S.J., Munck A., Craig J.V., Sermet I., Brownlee K.G., Schwarz M.J., et al. A European consensus for the evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis. J Cyst Fibros 2009, 8:71-78.
14. Barben J., Ammann R.A., Metlagel A., Schoeni M.H. Conductivity determined by a new sweat analyzer compared with chloride concentrations for the diagnosis of cystic fibrosis. J Pediatr 2005, 146:183-188.
15. Liechti-Gallati S., Schneider V., Neeser D., Kraemer R. Two buffer PAGE system-based SSCP/HD analysis: a general protocol for rapid and sensitive mutation screening in cystic fibrosis and any other human genetic disease. Eur J Hum Genet 1999, 7:590-598.
16. Tluczek A., Mischler E.H., Farrell P.M., Fost N., Peterson N.M., Carey P., et al. Parents' knowledge of neonatal screening and response to false-positive cystic fibrosis testing. J Dev Behav Pediatr 1992, 13:181-186.
17. Mischler E.H., Wifond B.S., Fost N., Laxova A., Reiser C., Sauer C.M., et al. Cystic fibrosis newborn screening: impact on reproductive behaviour and implications for genetic counselling. Pediatrics 1998, 102:44-52.
18. Massie J., Curnow L., Tzanakos N., Francis I., Robertson C.F. Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing. Arch Dis Child 2006, 91:222-225.
19. Massie R.J., Olsen M., Glazner J., Robertson C.F., Francis I., et al. Newborn screening for cystic fibrosis in Victoria: 10years' experience (1989-1998). Med J Aust 2000, 172:584-587.
20. Massie R.J.H., Curnow L., Glazner J., Armstrong D.S., Francis I. Lessons learned from 20years of newborn screening for cystic fibrosis. Med J Aust 2012, 196:67-70.
21. Torresani T., Fingerhut R., Gallati S., Schoeni M.H., Baumgartner M.R., Barben J. Newborn screening for cystic fibrosis in Switzerland - consequences after analysis of 4months pilot study. J Cyst Fibros 2012, 11(Suppl. 1):S 59.